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INTRODUCTION
 Diabetic nephropathy (DN) is a disease of 
multifactorial pathogenesis involving several 
pathways which ultimately progress to reduction 
of renal functions.1,2 Estimated figures show that 
around 10-30% of type I diabetes mellitus and 15-
40% of type II diabetes mellitus patients suffer 
from DN.2 Activation of protein kinase C, increased 
production of advanced glycosylation end products 
(AGEs), and diacylglycerol synthesis are proposed 
as some of the triggers for progression of DN. Other 
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ABSTRACT
Background & Objective: Kidney Injury Molecule-1 (KIM-1) is a peptide whose release into circulation 
is specific to tubular injury. This study aimed to estimate levels of kidney injury molecule-1 in diabetic 
patients with and without kidney disease. And evaluate the role of KIM-1 as an early screening marker of 
progressive kidney injury.
Methods: This follow-up study included n=85 subjects from the diabetic clinic of Jinnah Post Graduate 
Medical Center (JPMC) in collaboration with Aga Khan University from November 2016 till September 2017 
They were divided as: i) Group A1 (n=30) participants with diabetes for <5 years without microalbuminuria 
ii) Group A2 (n= 30) subjects with diabetes for 6-10 years with microalbuminuria; iii) Group B (n=25) 
subjects as healthy control group. All study participants were followed for 6 months and their blood 
glucose, urea, creatinine, electrolytes, albuminuria and serum KIM-1 were assayed. 
Results: High KIM-1 at baseline was present in group A2 patients as compared to controls and group 
A1 (p<0.001). Higher levels were seen after six months in group A1 along with the presence of micro 
albuminuria (p<0.001) suggesting kidney damage. Moderate positive association were seen for KIM1 with 
creatinine levels (r=0.530; p<0.001), and HbA1c (r=0.576; p<0.001) in all patients. While a strong positive 
association was seen for blood urea nitrogen as a marker for kidney function both at baseline (r= 0.728; 
p=0.000) and follow up (r=0.747; p=0.001). Multiple logistic regression controlling for age showed that 
KIM1 was independently associated with BUN (r=0.727; p<0.001), creatinine (r=0.510; p<0.001) and HbA1c 
(r=0.401; p=0.008) in all groups.
Conclusion: Rising KIM-1 levels with progressive kidney damage with or without derangement of kidney 
function is reported in this study. This finding may pave a way towards identifying KIM1 as a prognostic 
marker for kidney injury.
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mechanism of renal damage in diabetes includes 
hemodynamic alterations such as glomerular hyper 
filtration, micro albuminuria and the metabolic 
changes.3,4
 Diagnosis and prognosis of DN largely depends 
on traditional markers such as estimated glomerular 
filtration rate (e-GFR) and albuminuria however, 
the gold standard for diagnosing DN is performing 
a renal biopsy which is less commonly used due to 
its invasive nature. Contrarily, micro albuminuria 
has been used as a diagnostic marker for >30 
years for renal injury. But recent data suggests the 
inability of micro albuminuria changes to foresee 
the nephropathy progression because in at least 
33% of  patients renal decline has already ensued.2,4 
Similarly, derangement of GFR is an indicator of 
DN but it can only detect the disease when it has 
progressed to incurable stage.5,6 Apart from these; 
conventional methods such as assessment of blood 
urea nitrogen and creatinine are routinely used but 
are quite insensitive and nonspecific, especially 
in the setting of acute kidney injury (AKI) in 
perspective of DN. This raises the urgent need of 
new and novel biomarkers which can precisely 
predict AKI.5,6
 Kidney injury molecule-1 (KIM-1) is a type I 
trans membrane glycoprotein (having a sixcysteine 
immunoglobulin- like domain two N -glycosylation 
sites)7, that is expressed on renal proximal tubule 
epithelial cells and is believed to play a role in renal 
tubulo-interstitial damage. The normal reference 
level of serum KIM-1 reported is as <1 ng/ml.8 
Based on the observations and current knowledge it 
can be asserted that KIM-1 plays significant role in 
renal regeneration processes. This is because KIM-
1 being a differentiation and proliferation marker 
is totally undetected in normally functioning renal 
system and only expressed in tubular cells after 
renal injury.9,10 Post ischemia/injury removal of 
debris (apoptotic and necrotic cells), from the 
luminary surfaces is mandatory for remodeling, 
restoration processing and integrity of renal 
tissues. Ichimura et al. in 1998 postulated that the 
mechanism of removal of debris is dependent on 
the role of KIM-1.11 KIM-1-expressing epithelial 
cells exhibit strong phagocytic ability in vivo. 
Furthermore; it is KIM-1 that specifies the site 
of dead cells and simultaneously mediates these 
phagocytic properties.11 Therefore, the aim of 
this study was to estimate levels of kidney injury 
molecule-1 in diabetic patients with and without 
kidney disease. And evaluate the role of KIM-1 as 
an early screening marker of kidney injury.
METHODS
 This follow up study included 112 participants 
between the age of 35-65 year from the diabetic 
clinic of Jinnah Post Graduate Medical Center 
(JPMC) in collaboration with Aga Khan University 
from November 2016 till September 2017. Out of 
the n=112 patients, we were able to follow n=85 
patients with a drop out of 27 patients. Taking 
the prevalence of diabetic kidney disease as 16.9% 
margin of error at 5% with confidence interval of 
95%, and the power of 80% a minimum sample size 
of 83 subjects was required to conduct this study.
 The diagnosis of diabetes was made as per 
recommendation of American diabetic association12 
and diagnosis of diabetic nephropathy was made 
by performing spot urine protein to check for either 
the presence of microalbuminuria (30–299 mg/mL) 
with increased frequency of metabolic syndrome 
components, stable GFR (creatinine and BUN) and/
or macroalbuminuria >300 mg/mL in two of three 
spot urine specimens, progressive GFR decline, 
hypertension or any other comorbid.13
 While patients with chronic systemic disease 
(Cardiovascular, Urogenital, Immunological 
etc.), history of DM for >10 years, patients on 
nephrotoxic drugs, anti-inflammatory drugs and 
on dialysis were excluded from this study. All 
procedures were in accordance with the ethical 
standards of the institutional review committee of 
Basic Medical Sciences Institute, JPMC Karachi (Ref 
NO.F.2-81-IRB/2017/GENL/419/JPMC), Pakistan. 
All participants were informed about the study and 
gave a written and informed consent to participate. 
These study participants were divided into the 
following groups: Group A1 (n=30) diabetes for <5 
year without microalbuminuria; Group A2 (n=30) 
diabetes for 5-10 year with microalbuminuria and 
Group B (n=25) healthy control subjects. All study 
participants were followed for 6 months. Blood 
samples from each participants were obtained in 
the morning after an overnight fast of 8 hours at 
baseline and at 6 months follow up. Serum was 
separated and stored at -80◦C and was used to 
measure complete blood count, blood glucose, 
HbA1c, serum electrolytes, urea/creatinine levels 
by automation and KIM-1 levels by sandwich 
ELISA (Glory Science Co., Ltd, Cat. NO 11138). 
Midstream Urine was collected for dipstick urine 
albumin test and spot urine albumin at baseline and 
6 month follow up.
Statistical Analysis: Statistical software SPSS 
version 21.0 was used for data feeding and analysis. 
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A descriptive statistical analysis of continuous 
variables was performed. Data on continuous 
variables i.e. biophysical (age, height, weight, BMI, 
blood pressure, blood glucose etc.) and biochemical 
(Serum urea, creatinine, electrolytes, and serum 
KIM-1 etc.) parameters were presented as Mean 
+ standard deviation (SD). One way analysis of 
variance (ANONA) with post hoc Tukeys test was 
used to compare groups. Pearson coefficient of 
correlation (r) was used to relate the levels of serum 
KIM-1. A p-value ≤0.05 was considered significant.
RESULTS
 Mean age of groups A1 and A2 were comparable 
(p>0.05) while group B was on the lower age 
bracket (p=0.01). HbA1c, FBG and RBG levels were 
higher in diabetic patients as compared to controls 
(p< 0.005). BUN, Urea creatinine levels were 
significantly higher in groups A1 and A2 (p<0.01) 
as compared to controls; whereas no difference 
was seen for serum electrolytes among groups 
(p>0.05). The comparison of serum KIM1 levels 
in study subjects is shown in Table-II. Elevated 
levels of KIM1 at baseline were seen in patients 
with more than five year of diabetes as compared 
to controls and patients with less than five year 
diabetes (p<0.001). When we compared the levels 
after 6 months a rising trend was observed for KIM-
1 in group A-1 subjects along with the presence of 
micro albuminuria. This showed that their kidney 
function was being progressively affected and 
there was damage to the kidney itself.  Moderate 
positive association were seen for KIM1 with 
age (r=0.425; p=0.012), creatinine levels (r=0.530; 
p<0.001), and HbA1c (r=0.576; p<0.001) levels in 
all patients. While a strong positive association 
was seen for blood urea nitrogen as a marker for 
kidney function both at baseline (r= 0.728; p=0.000) 
and follow up (r=0.747; p=0.001). Multiple logistic 
regression controlling for age showed that KIM1 
KIM-1 and Diabetic Nephropathy
Table-I: Baseline status of the study subjects.
Variables A1 Diabetes for  A2 Diabetes for B Controls p-value
 <5 year without 5-10 year with (n=25)
 microalbuminuria (n=30) microalbuminuria (n=30)
Age (Years) 45.70±10.27^ 46.72±13.37# 29.8±6.4 <0.001
Weight (kg) 69.16±11.44 70.96±16.51 61.86±7.08 0.049
BMI (kg/m2) 27.34±5.59^ 28.21±5.94# 22.81±2.69 0.003
Hemoglobin (mg/dL) 12.01±0.98* 10.76±1.87 11.23±0.53 0.005
HbA1c 7.286±0.74^ 7.43±1.03# 5.18±0.27 0.031
FBG at baseline (mg/dl) 136.77 + 45.19*,^ 172.44 ± 38.32# 87.86 ± 9.08 0.031
FBG at 6 months (mg/dl) 172.45 ± 62.56 ^ 190.66 ± 71.65# 79.55 ± 8.64 0.000
RBG at baseline (mg/dl) 163.77 ± 41.46* 202.71 ± 58.38# 156.66 ±58.06 0.007
RBG at 6 months (mg/dl) 150.81 ± 27.35* 233.85 ± 94.86# 158.22 ± 32.15 0.005
Blood Urea nitrogen (mg/dL) 11.79±2.75* 25.50±2.12# 12.67±3.47 0.000
Serum urea (mg/dL) 35.56±7.19*,^ 57.30±35.03# 27.11±7.42 0.000
Serum Creatinine (mg/dL) 0.73±0.17* 1.34±0.90# 0.84± 0.12 0.000
Serum Sodium (mmol/liter) 139.46±2.75 134.26±8.48 132.21±5.44 0.05
Serum Potassium (mmol/liter) 4.36±0.51 3.87±0.84 3.95±0.45 0.05
Values expressed as Mean ± SD. Comparison between groups was made by ANOVA with Tukey’s b applied as 
a posthoc test analysis. *A1compared with A2; ^ A1 compared with B; #A2 compared with B where statistically 
significant value was set at p<0.05.
Table-II: KIM-1 and urine albumin levels at baseline and follow up.
Variables A1 (n=30) A2 (n=30) B (n=25) p-value
Baseline KIM -1 Level (ng/ml) 20.91± 14.90 *,^ 24.86 ± 8.91# 7.52 ±0.77 <0.001
Follow up KIM -1 Level (ng/ml) 25.68±14.95^ 27.34 ± 3.93# 8.22 ± 0.83 <0.01
Baseline Urine Albumin (dipstick) Absent*,^ ++#,* Absent 0.001
Follow up Urine Albumin (dipstick)  ++ ^ +++ # Absent 0.001
Values expressed as Mean ± SD. Comparison between groups was made by ANOVA with Tukey’s b applied as 
a posthoc test analysis. *A1compared with A2; ^ A1 compared with B; #A2 compared with B where statistically 
significant value was set at p<0.05.
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was independently associated with BUN (r=0.727; 
p<0.001), creatinine (r=0.510; p<0.001) and HbA1c 
(r=0.401; p=0.008) in all groups.
DISCUSSION
 This present study aimed at finding out the role 
of KIM -1, a relatively new marker for diabetic 
nephropathy. KIM-1 levels progressively rose 
with the duration of diabetes. This manifestation 
of elevation of detectable level of serum KIM-1 
clearly shows that with the progression of diabetes 
and increasing duration, there is disruption of 
renal function and increase in severity of renal 
inflammation (nephropathy).
 Detection of KIM-1 in patients with a shorter 
duration of diabetes (Group A-1) in this study and 
elevated levels at six months follow up shows the 
progression of kidney injury with time. Diabetes is 
related to the deranged kidney functions that can 
remain undiagnosed many times. By measuring the 
levels at two different point in time and with different 
degree of disease severity in study participants; we 
were able to show that KIM-1 levels rises with the 
progression of kidney disease even when all other 
parameters such as BUN or creatinine level remain 
within the normal range. This finding is suggestive 
that as the kidney damage progressed, more KIM-1 
is secreted; therefore KIM-1 levels can be used for 
early detection of DN in diabetic patients.
 This is also true in conditions when the micro 
albuminuria has not been detected in the urine as 
was the case in this study. Various distinct studies 
have reported that early renal tubular damage 
biomarker levels (including urinary KIM-1 levels) 
are elevated in patients with diabetes, even in those 
with normal albuminuria.14-16 This highlights the 
importance of use of serum KIM-1 from screening 
perspective of diabetic patient’s for DN during the 
“tubular phase” of renal damage even before the 
development of albuminuria. Thus, serum KIM-1 
may be recommended as a biomarker for detecting 
early diabetic nephropathy.14,16,17-20 KIM-1 levels 
in this study showed strong positive association 
with blood urea nitrogen as a marker for kidney 
function both at baseline (r= 0.728; p value = 0.000) 
and follow up (r=0.843; p value = 0.001). Similar 
results were also observed in a study where they 
reported dramatic increase in urinary KIM-1 levels 
within 12 hour of initial ischemic renal insult, 
prior to the appearance of casts in urine. With this 
finding it was speculated that KIM-1 is not only 
a biomarker of kidney injury but also a predictor 
for the risk of developing ATN.4 While moderate 
positive association were seen for KIM-1 with age 
(r=0.425; p value = 0.012 and disease duration 
(r=0.430; p value = 0.011) which is similar to another 
study.21 It has been observed by various researches 
that longer the duration of diabetes worse is the 
prevalence of complications of diabetes.22,23 Serum 
KIM-1 may become as a highly specific predictor, 
useful and novel biomarker for early detections of 
declining renal functions in the diabetes mellitus 
type 2 patients.
 We were however limited to perform renal 
biopsies to confirm the degree of damage and also 
were unable to recruit subjects with more than 
10 years of disease as most of them suffered from 
either end stage kidney damage or were on dialysis 
and were non-compliant to the study follow up.
CONCLUSION
 Rising KIM-1 levels with progressive kidney 
damage with or without derangement of kidney 
function is reported in this study. This finding 
may pave a way towards identifying KIM1 as a 
prognostic marker for kidney injury.
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